At the 6th World Congress of Cutaneous Lymphoma, a group of world-leading CTCL expert consider what the field will abandon in the next decade.
Lena Specht, MD, DMSc
Advertisement
Lena Specht, MD, DMSc, is a professor of oncology at the Faculty of Health Sciences and Chief Oncologist at Rigshopitalet at the University of Copenhagen.
Articles by Lena Specht, MD, DMSc
Lena Specht, MD, DMSc, discusses data for mogamulizumab in Danish patients with mycosis fungoides or Sezary syndrome and their effect on clinical practice.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
2
The OncFive: Top Oncology Articles for the Week of 8/9
3
Dive into the Data Supporting the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
4
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
5